

TRICARE Prior Authorization Request Form for  
abatacept subcutaneous ( **Orencia SC** )



**JOHNS HOPKINS**  
HEALTH PLANS

7231 Parkway Drive, Suite 100, Hanover, MD 21076

**FAX Completed Form and  
Applicable Progress Notes to:  
(410) 424-4037**

## USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**Questions?** Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior Authorization does not expire.

**Step 1** Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

**Step 2** Please complete clinical assessment:

1. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No Proceed to question 4
2. Has the patient had an inadequate response to Humira?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No Proceed to question 3
3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
4. Does the patient have a contraindication to Humira (adalimumab)?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
5. Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosaliclates [for example: sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example, azathioprine], etc.)	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
6. Will the patient be taking the TNF antagonists at the same time as Orencia?	<input type="checkbox"/> Yes <b>STOP</b> Coverage not approved	<input type="checkbox"/> No Proceed to question 7
7. Is the patient the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No Proceed to question 9

TRICARE Prior Authorization Request Form for  
abatacept subcutaneous ( **Orencia SC** )

<b>8. What is the indication or diagnosis?</b>	<input type="checkbox"/> Moderate to severe active <b>rheumatoid arthritis</b> – Proceed to question <b>11</b> <input type="checkbox"/> Active <b>psoriatic arthritis</b> – Proceed to question <b>11</b> <input type="checkbox"/> Other indication or diagnosis – <b>STOP: Coverage not approved.</b>
<b>9. Is the patient the patient 2 to 17 years of age or older?</b>	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> Yes Proceed to question <b>10</b> </div> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> No <b>STOP</b> Coverage not approved                 </div> </div>
<b>10. What is the indication or diagnosis?</b>	<input type="checkbox"/> Moderately to severely active <b>polyarticular juvenile idiopathic arthritis</b> – Proceed to question <b>11</b> <input type="checkbox"/> Active <b>psoriatic arthritis</b> – Proceed to question <b>11</b> <input type="checkbox"/> Other indication or diagnosis – <b>STOP: Coverage not approved.</b>
<b>11. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?</b>	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> Yes Proceed to question <b>12</b> </div> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> No <b>STOP</b> Coverage not approved                 </div> </div>
<b>12. Will the patient be receiving other targeted immunomodulatory biologics with Orencia including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Otezla, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz, Tremfya or Xeljanz/Xeljanz XR?</b>	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> Yes <b>STOP</b> Coverage not approved                 </div> <div style="width: 45%; text-align: center;"> <input type="checkbox"/> No Sign and date below                 </div> </div>

**Step 3** I certify the above is true to the best of my knowledge. Please sign and date:

\_\_\_\_\_  
 Prescriber Signature Date

[26 June 2024]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: